Clinical Trials associated with Issar Pharmaceuticals Pvt Ltd.
CTRI/2012/04/002592
/ CompletedPhase 3
A phase III randomized, double blind, multi-center study of Xylentraâ?¢ versus Silver Sulfadiazine forefficacy and safety in patients with partial thickness burns in India
A PHASE 1, OPEN LABEL, NON-RANDOMIZED, MULTI-ARM, MULTI-CENTRE, PARALLEL SEQUENCE STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE AND THE DOSE LIMITING TOXICITY OF GENOPEP 1 (ISSAR 1) IN RELAPSED SOLID TUMOUR CANCER PATIENTS
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.